{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:50:36Z","timestamp":1761897036145},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mrs. A. is a 73-year-old woman who has developed increasing fatigue and lower back pain over the past year. The pain limits her exercise tolerance such that she can now walk only 1 block. She is a retired schoolteacher who does volunteer efforts in her community but has limited her activities due to fatigue. Karnofsky performance status is 70%. She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine. Initial evaluation reveals anemia, renal dysfunction, an elevated total protein, and an L2 compression fracture on lumbosacral radiographs. Results of initial and subsequent evaluation are shown below, and she is referred to a hematologist for further evaluation, which revealed the following: calcium 9.0 mg\/dL, creatinine 3.2 mg\/dL with estimated creatinine clearance using the Modification of Diet in Renal Disease equation of 15 mL\/min, hemoglobin 9.6 g\/dL, total protein 11 g\/dL, albumin 3.2 g\/dL, immunoglobulin A (IgA) \u03bb M protein 6.8 g\/dL, total IgA 7.2 g\/dL, IgG 0.4 g\/dL, IgM 0.03 g\/dL, free \u03ba &lt;0.01 mg\/L, free \u03bb 1000 mg\/L, free light chain ratio &lt;0.01, \u03b2-2\u2013microglobulin 4.2, viscosity 3.0, lactate dehydrogenase 200 U\/L, urine protein electrophoresis: 125 mg\/dL with 30% M protein, and urine immuno-electrophoresis: \u03bb light chain. Skeletal bone survey showed lytic lesions in femurs and humeri and diffusely in ribs bilaterally as well as compression fractures at T4, T6, and L2. Bone marrow biopsy revealed \u03bb-restricted plasma cells comprising 50% of the bone marrow core. Fluorescence in situ hybridization testing on marrow showed that del(17p) was present in 80% of the plasma cells. Mrs. A. is informed of the diagnosis of multiple myeloma and the need for therapy. She requests consultation with 2 of the leading world experts. However, she wants to be treated near her home and does not want treatment on a clinical trial.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.83","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"83-87","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist"],"prefix":"10.1182","volume":"2018","author":[{"given":"Thierry","family":"Facon","sequence":"first","affiliation":[{"name":"Department of Haematology, Centre Hospitalier Universitaire Lille, Lille, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Anderson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111521082847000_B1","unstructured":"Howlader N , NooneAM, KrapchoM, et al, eds. SEER cancer statistics review, 1975-2013. http:\/\/seer.cancer.gov\/csr\/1975_2013\/. Accessed 13 June 2018."},{"issue":"6","key":"2019111521082847000_B2","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"30","key":"2019111521082847000_B3","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, Phase III FIRST trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"2019111521082847000_B4","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"2019111521082847000_B5","unstructured":"European Medicines Agency. Points to consider on frailty: evaluation instruments for baseline characterisation of clinical trial populations. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/12\/WC500199243.pdf. Accessed 11 June 2018."},{"issue":"1","key":"2019111521082847000_B6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/geront\/10.1_Part_1.20","article-title":"Progress in development of the index of ADL","volume":"10","author":"Katz","year":"1970","journal-title":"Gerontologist"},{"issue":"3","key":"2019111521082847000_B7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"issue":"9","key":"2019111521082847000_B8","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2019111521082847000_B9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"2019111521082847000_B10","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"2019111521082847000_B11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2014.307","article-title":"The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma","volume":"111","author":"Wu","year":"2014","journal-title":"Br J Cancer"},{"issue":"suppl 4","key":"2019111521082847000_B12","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"2019111521082847000_B13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European Myeloma Network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"issue":"38","key":"2019111521082847000_B14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1200\/EDBK_205583","article-title":"Bones in multiple myeloma: imaging and therapy","volume":"2018","author":"Zamagni","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"26","key":"2019111521082847000_B15","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111521082847000_B16","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the Intergroupe Francophone du My\u00e9lome experience","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2019111521082847000_B17","first-page":"3040","article-title":"Factors predicting poor outcomes for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial","volume":"130","author":"Pawlyn","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2019111521082847000_B18","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"10068","key":"2019111521082847000_B19","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"2019111521082847000_B20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/bjh.15261","article-title":"A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma","volume":"182","author":"O\u2019Donnell","year":"2018","journal-title":"Br J Haematol"},{"issue":"24","key":"2019111521082847000_B21","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2019111521082847000_B22","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41375-018-0098-9","article-title":"Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents","volume":"32","author":"Avet-Loiseau","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2019111521082847000_B23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3324\/haematol.2015.133629","article-title":"Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma","volume":"101","author":"Dimopoulos","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"2019111521082847000_B24","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111521082847000_B25","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"2019111521082847000_B26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.14694\/EDBK_175171","article-title":"Myeloma in elderly patients: when less is more and more is more","volume":"37","author":"Rosko","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2019111521082847000_B27","doi-asserted-by":"crossref","article-title":"Autologous stem cell transplantation is safe and effective for older myeloma patients: results from the Myeloma XI trial","author":"Pawlyn","DOI":"10.3324\/haematol.2020.262360"},{"issue":"4","key":"2019111521082847000_B28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13608","article-title":"Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma","volume":"171","author":"Auner","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111521082847000_B29","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 1","key":"2019111521082847000_B30","first-page":"397","article-title":"Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02\/HO95 study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2019111521082847000_B31","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111521082847000_B32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"2019111521082847000_B33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111521082847000_B34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/83\/1252287\/hem01811.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/83\/1252287\/hem01811.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T03:15:36Z","timestamp":1663298136000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/83\/277578\/Treatment-approach-for-the-older-unfit-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.83","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}